CG3 On Other Exchanges
Sao Paulo
text size: T | T
Back to Snapshot
Company Description

Contact Info

86 Morris Avenue

Summit, NJ 07901

United States

Phone: 908-673-9000


Celgene Corporation, together with its subsidiaries, operates as an integrated biopharmaceutical company worldwide. The company engages primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The company’s primary commercial stage products include REVLIMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside of the United States), and ISTODAX. The company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. The company also has various potential products in phase III trials across multiple diseases. In the inflammation and immunology therapeutic area, the company has phase III trials underway for ozanimod in ulcerative colitis and relapsing multiple sclerosis, and for GED-0301 in Crohn’s disease (CD). In hematology, phase III trials are underway for CC-486 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), for AG-221 in AML, and for luspatercept in MDS. In August 2015, the company acquired Receptos, Inc. (Receptos). Receptos' major drug candidate, ozanimod, is a small molecule that modulates sphingosine 1-phosphate 1 and 5 receptors and it is in development for immune-inflammatory indications, including inflammatory bowel disease and relapsing multiple sclerosis. The acquisition of Receptos also included other pipeline and pre-clinical stage compounds. REVLIMID (lenalidomide): REVLIMID is an oral immunomodulatory drug marketed in the United States and various international markets. REVLIMID is in various phase III trials covering a range of hematological malignancies that include multiple myeloma, lymphomas, chronic lymphocytic leukemia and MDS. In January 2016, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for treatment with REVLIMID in adult patients with relapsed or refractory mantle cell lymphoma. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension): ABRAXANE is a solvent-free chemotherapy product, which is developed using the company’s proprietary nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. In solid tumors, ABRAXANE is in various stages of investigation for breast, pancreatic, gastric, and non-small cell lung cancers. POMALYST/IMNOVID-(pomalidomide): POMALYST/IMNOVID is a proprietary small molecule that is administered orally and modulates the immune system and other biologically important targets. POMALYST/IMNOVID was approved in the United States and the European Union for indications in multiple myeloma based on phase II and phase III trial results, respectively, and an additional phase III trial is underway with POMALYST/IMNOVID in relapsed and refractory multiple myeloma. OTEZLA (apremilast): OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. In inflammation and immunology, OTEZLA is being evaluated in phase III trials for Behçet's disease and expanded indications in psoriatic arthritis and plaque psoriasis. VIDAZA (azacitidine for injection): VIDAZA is a pyrimidine nucleoside analog that has been shown to reverse the effects of DNA hypermethylation and promote subsequent gene re-expression. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS. In 2013, the company contracted with Sandoz AG (Sandoz) to sell a generic version of VIDAZA in the United States, which the company supplies and recognizes net product sales from its sales to Sandoz. Regulatory exclusivity for VIDAZA is expected to continue in Europe through 2019. VIDAZA is marketed in the United States and many international markets for the treatment of patients with various indications, such as MDS, chronic myelomonocytic leukemia, and


The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CG3.
View Industry Companies

Industry Analysis


Industry Average

Valuation CG3 Industry Range
Price/Earnings 52.5x
Price/Sales 8.7x
Price/Book 16.5x
Price/Cash Flow 42.0x
TEV/Sales 6.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CELGENE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at